comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 23:03:08 - browse：89

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： STAT Readout Newsletter: Biotech news today

hotspot

WSS

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

How AI can help patients find reliable information about doctors

The problems with dementia villages

A new crop of companies is reshaping the health data economy

Rise in cancer among younger people worries and puzzles doctors

Merck, Daiichi strike cancer drug pact worth up to $22 billion

leisure time

comprehensive

knowledge

Jerome Adams on the need for new antivirals for Covid

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Guidelines to prevent youth baseball injuries need more muscle

J&J lung cancer data amount to new salvo against AstraZeneca

The high cost of giving birth even with insurance

Health tech investors get more selective as pandemic boom fades

Guidelines to prevent youth baseball injuries need more muscle

The haunting brain science of long Covid

After affirmative action ruling, medical educators look to 'holistic review'

The battle over 'scope creep' and who gets to be called 'doctor'

entertainment

Search called off for baby washed away in Pennsylvania flash flood

CZI to create biohub to build anti

J&J lung cancer data amount to new salvo against AstraZeneca

FDA clears Verve to begin U.S. study of gene

Roche drug slashes death risk in early

'Investigate these claims': UFO transparency at center of House hearing

hotspot

explore

knowledge

Wikipedia